Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialM. William Audeh, Andrew Tutt, James Carmichael et al.|The Lancet|2010Cited by 2.3k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, James Carmichael, Mark E. Robson et al.|The Lancet|2010Cited by 1.6k
Large-scale genotyping identifies 41 new loci associated with breast cancer riskKyriaki Michailidou, François Bacot, Melissa C. Southey et al.|Nature Genetics|2013Cited by 1.1k
MicroRNA Related Polymorphisms and Breast Cancer RiskSofia Khan, Marjanka K. Schmidt, Dario Greco et al.|PLoS ONE|2014Cited by 638
Genome-wide association analysis identifies three new breast cancer susceptibility lociMelissa C. Southey, Maya Ghoussaini, Olivia Fletcher et al.|Nature Genetics|2012Cited by 284